文献速递哮喘呼吸道感染

伊曲康唑与泼尼松龙治疗急性期变应性支气管肺曲霉病的随机试验

A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma.
PubMed 文献 · Chest · 2018-01-11

本研究为随机对照试验,纳入131例急性期变应性支气管肺曲霉病(ABPA)合并哮喘的初治患者,分别接受伊曲康唑或泼尼松龙单药口服4个月。

要点

  • 两组IgE下降百分比、急性发作次数及首次发作时间无显著差异。

核心结论

  • 泼尼松龙在诱导急性期ABPA应答方面优于伊曲康唑,但伊曲康唑在相当比例患者中有效且副作用更少,仍为初始治疗的有吸引力的替代选择。

研究设计与样本

  • 随机对照试验,纳入131例ABPA合并哮喘的初治患者,泼尼松龙组63例,伊曲康唑组68例,治疗4个月,非盲法。

主要发现

  • 6周和3个月时IgE下降百分比及1年和2年时急性发作次数两组相似。
  • 首次急性发作时间(均值437 vs 442天)及6周肺功能改善两组相似。

关键数值与推荐

  • 首次急性发作时间均值:泼尼松龙组437天,伊曲康唑组442天。

临床怎么用

  • 急性期ABPA合并哮喘患者可考虑泼尼松龙作为首选诱导治疗。
  • 对于不能耐受糖皮质激素副作用或存在禁忌的患者,伊曲康唑可作为替代选择。

局限性

  • 研究为非盲法设计。
  • 样本量有限(共131例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Whether itraconazole monotherapy is effective in the acute stage of allergic bronchopulmonary aspergillosis (ABPA) remains unknown. The goal of this study was to compare the efficacy and safety of itraconazole and prednisolone monotherapy in ABPA. METHODS: Treatment-naive subjects with ABPA complicating asthma (January 2012 to December 2013) were randomized to receive either oral itraconazole or prednisolone for 4 months. The study was not blinded. The primary outcomes were proportion of subjects exhibiting a composite response after 6 weeks, percent decline in IgE after treatment, and numbers of subjects experiencing exacerbation. The secondary outcomes included the time to first exacerbation, change in lung function, and treatment-related adverse effects. RESULTS: A total of 131 subjects (prednisolone group, n = 63; itraconazole group, n = 68) were included in the study. The number of subjects exhibiting a composite response was significantly higher in the prednisolone group compared with the itraconazole group (100% vs 88%; P = .007). The percent decline in IgE after 6 weeks and 3 months and the number of subjects with exacerbations after 1 and 2 years of treatment were similar in the two groups. The time to first exacerbation (mean: 437 vs 442 days) and the improvement in lung function after 6 weeks was also similar in the two groups. The occurrence of side effects was significantly higher in the glucocorticoid arm (P < .001). CONCLUSIONS: Prednisolone was more effective in inducing response than itraconazole in acute-stage ABPA. However, itraconazole was also effective in a considerable number and, with fewer side effects compared with prednisolone, remains an attractive alternative in the initial treatment of ABPA. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01321827; URL: www.clinicaltrials.gov).

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Dhooria S, Singh Sehgal I, et al. A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest. 2018. PMID: 29331473. doi:10.1016/j.chest.2018.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。